Skip to main content

Table 6 Relationship between p53 overexpression and clinicopathologic parameters

From: Prognostic role of serum p53 antibodies in lung cancer

  No. of cases No. of patients with p53 overexpression
Age (years)   
≤60 27 16 (59.3%)
>60 104 59 (56.7%)
Total 131 75 (57.3%)
Sex   
Male 101 57 (56.4%)
Female 30 18 (60.0%)
Total 131 75 (57.3%)
Histological type   
NSCLC   
Adenocarcinoma 59 26 (44.1%)
Squamous cell carcinoma 46 33 (71.7%)
Bronchioloalveolar carcinoma 5 1 (20.0%)
Large cell carcinoma 4 4 (100%)
Anaplastic carcinoma 4 4 (100%)
Mixed carcinoma 5 1 (20.0%)
SCLC 8 6 (75.0%)
Total 131 75 (57.3%)
NSCLC stage   
I 62 35 (56.4%)
II 17 9 (52.9%)
III 22 15 (68.2%)
IV 18 8 (44.4%)
Missing 4 2 (50.0%)
Total 123 69 (56.1%)
NSCLC grade   
G1 3 1 (33.3%)
G2 53 21 (39.6%)
G3 60 40 (66.7%)
Missing 7 7 (100%)
Total 123 69 (56.1%)